EUCTR2005-005393-73-DE进行中（未招募）不适用
A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to Associate PET Findings with Molecular Markers - ERLOPET
niversity Cologne0 个研究点目标入组 40 人开始时间: 2007年12月14日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. First diagnosis of histologically proven advanced non-small cell lung cancer 2. Tumor tissue available and suitable for EGFR gene resequencing 3. At least one measurable lesion according to RECIST 4. No prior standard chemotherapy, immunotherapy or small-molecules therapy 5. = 18 years of age 6. ECOG performance status 0-2 7. Patient's own, written informed consent to participate in the trial 8. TSH, FT3 and FT4 serum levels compatible with contrast enhanced CT (no signs of hyperthyroidism) 9. Renal laboratory parameters compatible with contrast enhanced CT (serum creatinine ? 1,7 mg/dl) 10. No decompensated liver failure 11. No decompensated heart failure 12. No clinical or radiological sign of interstitial lung disease, no interstitial lung disease in the past 13. Life expectancy > 3 months 14. In case of female patients with childbearing potential: - negative pregnancy test - effective method of contraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Lack of appropriate biopsy specimen for EGFR gene re-sequencing 2. Previous systemic treatment of NSCLC (chemotherapy, immuntherapy, therapy with small molecules and others) 3. Concurrent systemic immune therapy, chemotherapy, or therapy with any anticancer drug not indicated in the study protocol 4. Solitary metastases accessible to surgical resection 5. Bone metastases which have to be treated by radiotherapy (e.g. impending fracture), if no additional metastases outside the radiation field are present 6. Tumor masses with acute risk of life-threatening complications (e.g. compression of large arteries or trachea) which require emergency treatment (e.g. radiotherapy) 7. Malignant disease other than NSCLC within the last 5 years (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma pT1N0M0 (Clark level II)) 8. Infection with HIV, Hepatitis B, Hepatitis C 9. Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the trial and to formulate his/her own wishes adequately 10. Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information 11. Any person being in an institution on assignment of the respective authority 12. Simultanous participation in any other clinical trial 13. Pregnancy, lactation 14. Diabetes mellitus 15. Elevated fasting blood glucose levels > 130 mg/dl (exception: reduction of an unexpectedly high blood glucose level to a value ? 130 mg/dl using regular insulin)
研究者
相似试验
进行中（未招募）
不适用
Clinical Trial testing the combination of MK-5172 and MK-8742 with Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2, 4, 5 and 6MedDRA version: 16.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 16.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-GBMerck Sharp & Dohme Corp.100
进行中（未招募）
1 期
A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype AFanconi anemia (subtype A)MedDRA version: 20.0Level: LLTClassification code 10055206Term: Fanconi's anemiaSystem Organ Class: 100000004850EUCTR2018-002502-31-ESRocket Pharmaceuticals, Inc.5
进行中（未招募）
1 期
A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype AFanconi anemia (subtype A)MedDRA version: 20.0Level: LLTClassification code 10055206Term: Fanconi's anemiaSystem Organ Class: 100000004850EUCTR2018-002502-31-GBRocket Pharmaceuticals, Inc.5
进行中（未招募）
1 期
Clinical Trial testing the combination of MK-5172 with/without MK-8742 and/or Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2/4/5/6MedDRA version: 17.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.0Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,100
进行中（未招募）
不适用
Clinical Trial testing the combination of MK-5172 and MK-8742 with Ribavirin in people with Hepatitis CHepatitis C Virus Genotype 2MedDRA version: 14.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002169-21-ESMerck Sharp & Dohme Corp.70